Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

Summary by AI BETAClose X

Ipsen announced positive results from the Phase IV DIRECTION trial comparing Dysport® to Botox® in adults with upper limb spasticity, showing Dysport had a non-inferior safety profile with a treatment-emergent adverse event rate of 20.3% versus 23.0% for Botox. The study also demonstrated a longer duration of effect for Dysport, lasting 14.2 weeks compared to 13.8 weeks for Botox, reinforcing its established safety and efficacy in managing spasticity symptoms.

Disclaimer*

Companies

Ipsen SA (0MH6)
UK 100

Latest directors dealings